Zhao Yakun, He Lihua, Sun Lu, Liu Wentao, Wang Hairui, Zhang Jianzhong, Gong Yanan, Wang Xiaohui
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Department of Health Statistics, China Medical University, Shenyang, China.
Front Microbiol. 2025 Mar 26;16:1553734. doi: 10.3389/fmicb.2025.1553734. eCollection 2025.
Metronidazole (MNZ) is widely used to treat infection worldwide. However, due to excessive and repeated use, resistance rates have exceeded 90% in some regions. The mechanisms of MNZ resistance have been extensively studied, and RdxA has been identified as the primary enzyme responsible for MNZ activation. Mutations in RdxA, particularly termination mutations, can lead to high-level MNZ resistance.
We identified a strain, ICDC15003s, which harbored RdxA termination mutation but remained highly susceptible to MNZ. To explore this phenomenon, we conducted comparative genomic and transcriptomic analyses to define RdxA-independent mechanisms of MNZ metabolism.
We found missense mutations in genes such as , , , , and . Additionally, the expression of multiple genes, including TonB-dependent receptor and mod, significantly changed in resistant strains. Notably, the sequences and expression levels of known nitroreductases like FrxA and FdxB remained unchanged after induction of MNZ resistance, suggesting they were not responsible for MNZ sensitivity in ICDC15003s. Instead, transcriptional alterations were observed in genes encoding NADH-quinone oxidoreductase subunit (M, J, H and K), suggesting a potential compensatory mechanism for the loss of RdxA activity. We proposed that NADH-quinone oxidoreductase might serve as an RdxA-independent mechanism for MNZ metabolism and resistance through regulation of its expression levels. This discovery could provide new strategies to address MNZ resistance and aid in developing nitroimidazole antibiotics.
甲硝唑(MNZ)在全球范围内被广泛用于治疗感染。然而,由于过度和反复使用,某些地区的耐药率已超过90%。甲硝唑耐药机制已得到广泛研究,RdxA被确定为负责甲硝唑激活的主要酶。RdxA中的突变,特别是终止突变,可导致高水平的甲硝唑耐药。
我们鉴定出一株菌株ICDC15003s,其携带RdxA终止突变,但对甲硝唑仍高度敏感。为探究这一现象,我们进行了比较基因组和转录组分析,以确定甲硝唑代谢的RdxA非依赖机制。
我们在诸如 、 、 、 和 等基因中发现了错义突变。此外,包括TonB依赖性受体和mod在内的多个基因的表达在耐药菌株中显著变化。值得注意的是,在诱导甲硝唑耐药后,已知的硝基还原酶如FrxA和FdxB的序列和表达水平保持不变,这表明它们与ICDC15003s对甲硝唑的敏感性无关。相反,在编码NADH-醌氧化还原酶亚基(M、J、H和K)的基因中观察到转录改变,这表明可能存在一种补偿机制来弥补RdxA活性的丧失。我们提出,NADH-醌氧化还原酶可能通过调节其表达水平,作为甲硝唑代谢和耐药的RdxA非依赖机制。这一发现可为解决甲硝唑耐药问题提供新策略,并有助于开发硝基咪唑类抗生素。